April 6, 2018 — Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA) approach together with the CyberKnife System. The patient, treated for oligometastases in the pelvic region, is part of a new clinical trial conducted at Erasmus MC, the largest university medical center in the Netherlands, evaluating OA stereotactic body radiation therapy (SBRT) delivered by the CyberKnife platform. The trial brings the hospital one step closer to its goal of providing individual, personalized medicine.
"At Erasmus MC our goal is to use innovative approaches to provide customized, effective treatments that help extend or improve the quality of life of people diagnosed with cancer, regardless of the stage of their cancer diagnosis," said J.J. Nuyttens, M.D., Ph.D., radiation oncologist, Department of Radiation Oncology, Erasmus MC. "We initiated this trial because we want to improve local cancer control and minimize toxicities in people with pelvic or intra-abdominal oligometastases."
Oligometastastic disease occurs when cancer cells from the primary tumor travel to other parts of the body and form a small number (less than six) of lesions. The cancerous cells are in an intermediate state; they are no longer confined to their initial location nor have they spread widely throughout the body. Radiation treatment of oligometastatic disease in the pelvic or intra-abdominal area is challenging because of the close proximity of healthy organs very sensitive to radiation. From one day to the next there can be a significant variation in the position of these organs, and it can be difficult to account for the changes in their location on a daily basis.
To address this issue, Accuray and Erasmus MC are partnering to develop an integrated, advanced imaging solution tailored for use with the CyberKnife System. The purpose is to enable clinicians to adapt the treatment plan to daily anatomical changes within the patient. According to Nuyttens, "this OA-SBRT strategy provided the treated patient with an optimal combination of dose to the tumor and sparing of the surrounding healthy organs."
This study is a non-randomized single arm phase II clinical trial evaluating the use of OA-SBRT for the treatment of oligometastatic disease in the pelvic or para-aortic region. In total, 53 patients will be enrolled and will be followed for three years. A prescription dose of 45 Gy will be delivered in five fractions by the CyberKnife System. The primary study objectives are to evaluate local control, survival and toxicity.
For more information: www.accuray.com
April 17, 2024 
